Transamerica Financial Advisors Inc. Raises Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Transamerica Financial Advisors Inc. increased its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 99.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,459 shares of the biopharmaceutical company’s stock after purchasing an additional 1,729 shares during the quarter. Transamerica Financial Advisors Inc.’s holdings in Royalty Pharma were worth $98,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Versant Capital Management Inc raised its holdings in Royalty Pharma by 5,215.0% in the 2nd quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,043 shares during the period. Gladius Capital Management LP acquired a new position in Royalty Pharma in the 2nd quarter worth about $32,000. Blue Trust Inc. raised its holdings in Royalty Pharma by 362.7% in the 3rd quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 943 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 655 shares during the period. Finally, iA Global Asset Management Inc. raised its holdings in shares of Royalty Pharma by 274.7% during the second quarter. iA Global Asset Management Inc. now owns 6,388 shares of the biopharmaceutical company’s stock valued at $168,000 after acquiring an additional 4,683 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Price Performance

RPRX stock opened at $26.60 on Thursday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. The business has a 50 day simple moving average of $27.19 and a 200-day simple moving average of $27.35. The firm has a market capitalization of $15.67 billion, a PE ratio of 13.78, a price-to-earnings-growth ratio of 4.65 and a beta of 0.47. Royalty Pharma plc has a 1 year low of $25.10 and a 1 year high of $31.66.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a $0.21 dividend. The ex-dividend date is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.16%. Royalty Pharma’s dividend payout ratio (DPR) is presently 43.52%.

Wall Street Analysts Forecast Growth

RPRX has been the subject of a number of research analyst reports. Citigroup reduced their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, October 25th. The Goldman Sachs Group increased their target price on Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $41.67.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.